EGFR and colorectal cancer: Is the lack of response in colorectal cancer due to the presence of additional anomalies that co-occur with BRAF mutations, or because BRAF inhibition causes feedback activation of EGFR [72], or because BRAF mutations are not driver abnormalities in colorectal cancer?